Canada markets closed
  • S&P/TSX

    17,779.41
    -126.61 (-0.71%)
     
  • S&P 500

    3,849.62
    -5.74 (-0.15%)
     
  • DOW

    30,937.04
    -22.96 (-0.07%)
     
  • CAD/USD

    0.7862
    -0.0017 (-0.21%)
     
  • CRUDE OIL

    52.86
    +0.25 (+0.48%)
     
  • BTC-CAD

    40,330.77
    -1,035.50 (-2.50%)
     
  • CMC Crypto 200

    638.67
    -8.65 (-1.34%)
     
  • GOLD FUTURES

    1,843.90
    -7.00 (-0.38%)
     
  • RUSSELL 2000

    2,149.86
    -13.42 (-0.62%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • NASDAQ futures

    13,548.00
    +62.50 (+0.46%)
     
  • VOLATILITY

    23.02
    -0.17 (-0.73%)
     
  • FTSE

    6,654.01
    +15.16 (+0.23%)
     
  • NIKKEI 225

    28,634.43
    +88.25 (+0.31%)
     
  • CAD/EUR

    0.6464
    -0.0011 (-0.17%)
     

DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019

MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA. DiaMedica’s President and CEO, Rick Pauls, will be hosting one-on-one meetings with institutional investors at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

For more information, please visit www.diamedica.com.

Contact:

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

Paul Papi
Vice President of Business Development
Phone: (617) 899-5941
info@diamedica.com